Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 181 participants.

Also called NCT01208233

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 181 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01208233
  • EudraCT 2010-021414-32
Other papers using this trial's data
  • Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016-03 DOI, PubMed 26738812

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, France, Germany, Hungary, India, South Korea, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01208233. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2016-02-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Intervention (Drug)
PF-03049423
Intervention (Drug)
PF-03049423
Intervention (Drug)
PF-03049423
Intervention (Other)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01208233
Content hash
488b278a832cb47748908321dc7b73b9eff40e58439efae739317062bb3e7a72